NRIX Nurix Therapeutics, Inc.companySEC Filings & Insider Trading Activity 2026
Latest Nurix Therapeutics, Inc. (NRIX) SEC EDGAR filings in 2026 — including the most recent 10-K annual report filed on January 28, 2026, a 10-Q quarterly report filed on April 8, 2026, an 8-K current report filed on April 8, 2026. SignalX aggregates every new 10-K annual report, 10-Q quarterly report, 8-K current report, and Form 4 insider transaction for Nurix Therapeutics, Inc. (NRIX) (SEC CIK 1549595), with AI-powered section-by-section summaries updated daily.
Latest 2026 SEC Filing Dates
AI 10-K Annual Report AnalysisLatest 10-K (2025-11-30)
Business Overview
- • Clinical stage biopharma focused on targeted protein degradation using AI-integrated DEL-AI platform for oncology, inflammation, and immunology treatments
- • Advanced lead BTK degrader bexobrutideg in Phase 2 pivotal trial with FDA Fast Track and EMA PRIME designations for relapsed/refractory CLL and WM
Risk Factors
- • Regulatory risk: FDA partial clinical hold on zelebrudomide enrollment in 2023 due to manufacturing change, lifted in August 2024
- • Macroeconomic risk: Uncertainty from inflation, interest rates, tariffs, debt ceiling risks, and global conflict impacts clinical trials, supply chain, personnel
Management Discussion & Analysis
- • No revenue figures or profitability metrics disclosed in provided text
- • No segment performance data available
AI 8-K Current Report AnalysisRecent 8-K Filings
Item 8.01: Other Events
- • ATM offering program expanded via Amendment No. 3 (March 6, 2026) with Piper Sandler as sales agent
- • Total program size set at $413.65M, inclusive of shares already sold under prior amendments — net new capacity is less than this figure
Annual Reports Archive10-K
AI-powered analysis of Nurix Therapeutics, Inc. (NRIX) 10-K annual reports filed with SEC EDGAR.
Quarterly Reports Archive10-Q
AI-powered analysis of Nurix Therapeutics, Inc. (NRIX) 10-Q quarterly reports filed with SEC EDGAR.
Recent 8-K FilingsCurrent Reports
AI-powered analysis of Nurix Therapeutics, Inc. (NRIX) 8-K current reports disclosing material events.
Financial SummaryXBRL
| FY2022 | FY2023 | FY2024 | FY2025 | |
|---|---|---|---|---|
| Profitability | ||||
| Revenue | $38.6M | $77.0M | $54.5M | $84.0M |
| Operating Income | -$183.9M | -$155.1M | -$213.0M | -$285.7M |
| Net Income | -$180.4M | -$143.9M | -$193.6M | -$264.5M |
| Op. Margin | -476.0% | -201.4% | -390.5% | -340.2% |
| Net Margin | -466.9% | -187.0% | -354.9% | -314.9% |
| Balance Sheet | ||||
| Total Assets | $416.8M | $355.6M | $669.3M | $688.1M |
| Equity | $303.7M | $200.5M | $527.0M | $538.7M |
| ROE | -59.4% | -71.8% | -36.7% | -49.1% |
Source: XBRL financial data from Nurix Therapeutics, Inc. (NRIX) 10-K filings on SEC EDGAR. All figures in USD. Key metrics include revenue, net income, gross profit, gross profit margin, operating income, EPS (diluted), total assets, stockholders' equity, return on equity (ROE), operating cash flow, and capital expenditure.
Latest 2026 SEC Filings — 10-K, 10-Q, 8-K & Form 4
| Form | Filing Date | Period | Analysis | SEC |
|---|---|---|---|---|
10-Q | Apr 8, 2026 | Feb 28, 2026 | — | |
8-K | Apr 8, 2026 | — | — | — |
8-K | Mar 6, 2026 | — | Analysis | — |
10-K | Jan 28, 2026 | Nov 30, 2025 | Analysis | |
8-K | Jan 28, 2026 | — | — | |
8-K | Jan 12, 2026 | — | — | |
8-K | Dec 9, 2025 | — | — | |
10-Q | Oct 9, 2025 | Aug 31, 2025 | Analysis | |
10-Q | Jul 9, 2025 | May 31, 2025 | — | |
10-Q | Apr 8, 2025 | Feb 28, 2025 | — | |
10-K | Jan 28, 2025 | Nov 30, 2024 | — | |
10-Q | Oct 11, 2024 | Aug 31, 2024 | — | |
10-Q | Jul 11, 2024 | May 31, 2024 | — | |
10-Q | Apr 10, 2024 | Feb 29, 2024 | — | |
10-K | Feb 15, 2024 | Nov 30, 2023 | — | |
10-Q | Oct 12, 2023 | Aug 31, 2023 | — | |
10-Q | Jul 13, 2023 | May 31, 2023 | — | |
10-Q | Apr 13, 2023 | Feb 28, 2023 | — | |
10-K | Feb 9, 2023 | Nov 30, 2022 | — | |
10-Q | Oct 6, 2022 | Aug 31, 2022 | — | |
10-Q | Jul 7, 2022 | May 31, 2022 | — | |
10-Q | Apr 8, 2022 | Feb 28, 2022 | — | |
10-K | Jan 28, 2022 | Nov 30, 2021 | — | |
10-Q | Oct 14, 2021 | Aug 31, 2021 | — | |
10-Q | Jul 13, 2021 | May 31, 2021 | — |
Frequently Asked Questions
What are the latest NRIX SEC filings in 2026?
Nurix Therapeutics, Inc. (NRIX) has filed a 10-K annual report on January 28, 2026, a 10-Q quarterly report on April 8, 2026, an 8-K current report on April 8, 2026 with the SEC. SignalX tracks every new SEC EDGAR filing daily, including 10-K, 10-Q, 8-K, and Form 4 insider transactions, with AI-powered summaries of key sections.
When did NRIX file its most recent 10-K annual report?
Nurix Therapeutics, Inc. (NRIX) filed its most recent 10-K annual report on January 28, 2026. The 10-K includes audited financial statements, business overview, risk factors, and management discussion, all available on SignalX with AI-generated summaries and XBRL financial data.
How do I view NRIX 10-Q quarterly reports?
Nurix Therapeutics, Inc. (NRIX)'s most recent 10-Q quarterly report was filed on April 8, 2026. SignalX displays every NRIX 10-Q with AI-generated summaries of the MD&A (Management Discussion & Analysis) and Risk Factors sections, plus links to the original SEC EDGAR document.
What 8-K current reports has NRIX filed recently?
Nurix Therapeutics, Inc. (NRIX)'s most recent 8-K was filed on April 8, 2026. 8-K filings disclose material corporate events such as earnings releases, executive changes, mergers, and other significant developments. SignalX surfaces each 8-K with item-level summaries so you can quickly see what happened.
Where can I find NRIX insider trading activity (Form 4)?
SignalX aggregates every NRIX Form 4 insider transaction from SEC EDGAR. Form 4 reports show when officers, directors, and 10% shareholders buy or sell company stock, with transaction code, share count, and price per share.
How often does NRIX file with the SEC?
Nurix Therapeutics, Inc. (NRIX) files a 10-K annual report once per year (typically within 60 days of fiscal year-end) and 10-Q quarterly reports three times per year. 8-K current reports are filed as needed when material events occur, and Form 4 insider transaction reports are due within two business days of a trade. SignalX monitors SEC EDGAR daily to surface every new NRIX filing with AI-powered analysis.
What is the difference between 10-K, 10-Q, and 8-K SEC filings?
A 10-K is a comprehensive annual report with audited financials, business overview, and risk factors. A 10-Q is a shorter quarterly report with unaudited financials and management discussion. An 8-K is a current report filed when a material event occurs — such as earnings releases, executive changes, acquisitions, or other significant developments. SignalX provides AI-generated summaries for all three filing types for Nurix Therapeutics, Inc. (NRIX).
What is NRIX's SEC CIK number?
Nurix Therapeutics, Inc. (NRIX)'s SEC CIK (Central Index Key) number is 1549595. The CIK is a unique identifier assigned by the SEC to every filing entity. You can use CIK 1549595 to look up all NRIX filings on SEC EDGAR, or browse them here on SignalX with AI-powered analysis.
Where can I find NRIX return on equity (ROE) and financial data?
SignalX extracts XBRL financial data from Nurix Therapeutics, Inc. (NRIX) 10-K annual filings, including revenue, net income, gross profit, operating income, EPS, total assets, stockholders' equity, and operating cash flow. Return on equity (ROE) can be derived from net income divided by stockholders' equity. Multi-year financial trends are displayed in the Financial Summary table above.
Stay on top of Nurix Therapeutics, Inc. SEC filings
Insider trading data, fund holdings, cross-signal detection, and AI-powered analysis for 28+ filings.